Neonatal sepsis: within and beyond China

Ying Dong¹, Romain Basmaci²,³, Luigi Titomanlio⁴, Bo Sun⁵, Jean-Christophe Mercier⁶

¹Department of Neonatology, Children’s Hospital of Fudan University, Shanghai 201102, China; ²Université de Paris, IAME, INSERM, 75018 Paris, France; ³Service de Pédiatrie-Urgences, AP-HP, Hôpital Louis-Mourier, 92700 Colombes, France; ⁴Pediatric Emergency Department, Robert Debre University Hospital, 75019 Paris, France; ⁵Departments of Pediatrics and Neonatology, Children’s Hospital of Fudan University, Shanghai 201102, China; ⁶Medical University of Paris, 75018 Paris, France.

Abstract
Sepsis remains a significant cause of neonatal morbidity and mortality in China. A better understanding of neonatal sepsis in China as compared with other industrialized and non-industrialized countries may help optimize neonatal health care both regionally and globally. Literature cited in this review was retrieved from PubMed using the keywords “neonatal sepsis,” “early-onset (EOS)” and “late-onset (LOS)” in English, with the focus set on population-based studies. This review provides an updated summary regarding the epidemiology, pathogen profile, infectious work-up, and empirical treatment of neonatal sepsis within and beyond China. The incidence of neonatal EOS and the proportion of Group B Streptococcus (GBS) within pathogens causing EOS in China seem to differ from those in developed countries, possibly due to different population characteristics and intrapartum/postnatal health care strategies. Whether to adopt GBS screening and intrapartum antibiotic prophylaxis in China remains highly debatable. The pathogen profile of LOS in China was shown to be similar to other countries. However, viruses as potential pathogens of neonatal LOS have been underappreciated. Growing antimicrobial resistance in China reflects limitations in adapting antibiotic regimen to local microbial profile and timely cessation of treatment in non-proven bacterial infections. This review stresses that the local epidemiology of neonatal sepsis should be closely monitored in each institution. A prompt and adequate infectious work-up is critically important in diagnosing neonatal sepsis. Adequate and appropriate antibiotic strategies must be overemphasized to prevent the emergence of multi-resistant bacteria in China.

Keywords: Antibiotic resistance; Blood culture; Early-onset sepsis; Late-onset sepsis; Neonatal sepsis; Nosocomial neonatal sepsis

Introduction
Neonatal sepsis is a cause of significant morbidity and mortality. Based on population-level studies during the last two decades, the global estimate of the incidence of neonatal sepsis was 2202 (95% confidence interval [CI] 1099–4360) per 100,000 live births (LBs), with mortality between 11% and 19%.¹,² In China, birth population-based surveys from one region that have approximated national average levels estimated the incidence of neonatal sepsis to be 25.6 per 1000 LBs.³ Between 1996 and 2015, the cause-specific mortality of neonatal sepsis in China decreased from 0.4 to 0.1 per 1000 LBs, which was significantly lower than the global estimate of 2.8 per 1000 LBs in 2015.⁴ Notably, great inequity exists in mortality rate of neonatal sepsis across regions in China.⁴ Clinical signs of neonatal sepsis range from sub-clinical infection to severe manifestations of focal or systemic disease.⁵ The pathogens responsible for sepsis might be acquired through in utero infection,⁶ maternal microbiota during delivery, or postnatal hospital or community environment.⁷ The timing of the exposure, inoculum size, immune status of the infant, and virulence of the causative micro-organism may greatly influence the clinical manifestations of neonatal sepsis. Based on different definitions across regions, early-onset sepsis (EOS) occurs within the first 3 to 6 days of life, whereas late-onset sepsis (LOS) occurs after 4 to 7 days within the first 1 to 3 months of life.⁸ Apart from the onset of time, there are marked differences in terms of pathogen profile and antimicrobial susceptibility among EOS, community-acquired LOS, and hospital-acquired LOS.⁹ In light of the above, great challenges exist to manage and reduce neonatal sepsis.

Access this article online
Quick Response Code: Website: www.cmj.org
DOI: 10.1097/CM9.0000000000000935

Correspondence to: Prof. Jean-Christophe Mercier, Medical University of Paris, 16 rue Henri Huchard, 75018 Paris, France
E-Mail: jean-christophe.mercier@sfr.fr
Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2020;Vol(No)
China is one of the most populous countries in the world with some regions closely approaching industrialized countries in terms of socioeconomic development and health care, while some relatively lagging behind. The second-child policy since 2015 may further complicate the clinical picture of neonatal sepsis. Therefore, this review will provide an updated summary regarding important aspects of neonatal sepsis, such as epidemiology, pathogen profiles, infectious work-up, and empirical treatment, both within and beyond China, in the hope of optimizing neonatal health care both regionally and globally.

**Early-Onset Neonatal Sepsis**

**Incidences and pathogen profiles**

**Industrialized countries**

In developed countries like USA, although the overall incidence of EOS has remained relatively stable at around 0.8 cases per 1000 LBs over the last two decades,[9] there have been marked changes in the pathogen-specific incidence of EOS. Group B Streptococcus (GBS) and *Escherichia coli* are predominant pathogens of neonatal EOS, accounting for 36% and 25% of EOS cases identified in four US States from 2005 to 2014.[9] Particularly, in the National Institute of Child Health and Human Development birth cohort of very low birth weight (VLBW) infants, there was a marked reduction in EOS caused by GBS (from 5.9 to 2.08 per 1000 LBs, *P* < 0.001), but an increase in *E. coli* sepsis (from 3.2 to 5.09 per 1000 LBs, *P* = 0.004) between 1991–1993 and 2006–2009.[10,11] In contrast, the incidence of GBS EOS plateaued or even slightly increased in some other developed countries [Table 1].[12,13] It has been speculated that different population structure, emergence of new GBS clones, increased recognition of EOS symptoms, and modified criteria for diagnosing neonatal sepsis might have contributed to higher incidence of GBS EOS over time in some regions.[13]

**Non-industrialized countries**

In contrast, the incidence of neonatal GBS EOS is less clear in developing countries, mainly due to limitations in

| Network          | Birth year | Population of cohort | No. of neonates | Onset of EOS (days) | Incidence of EOS (per 1000 LBs) | Case fatality |
|------------------|------------|----------------------|-----------------|--------------------|---------------------------------|---------------|
| USA              | NICHD[10]  | 1991–1993 VLBW       | 7606            | ≤3                 | All pathogens: 19.3             | NA            |
|                  |            |                      |                 |                    | GBS: 5.9 E. coli: 3.2           |               |
|                  | NICHD[11]  | 1998–2000 VLBW       | 5447            | ≤3                 | All pathogens: 15.4             | 31/84, 37%    |
|                  |            |                      |                 |                    | GBS: 1.7 E. coli: 6.8           |               |
|                  | 2006–2009  | All LBs              | 396,586         | ≤3                 | All pathogens: 0.98             | 61/389, 16%   |
|                  |            |                      |                 |                    | GBS: 0.41 E. coli: 0.28         | 15/160, 9%    |
|                  |            |                      |                 |                    |                                 | 35/107, 33%   |
|                  |            | VLBW                 | 12,956          | ≤3                 | All pathogens: 10.96            | NA            |
|                  |            |                      |                 |                    | GBS: 2.08 E. coli: 5.09         |               |
| UK               | CoSurv[12] | 2000–2001 All LBs    | 794,037         | ≤6                 | GBS: 0.48                       | 38/377, 10.6% |
|                  | NeonIN[13] | 2006–2008 All LBs    | 130,763         | ≤2                 | All pathogens: 0.9               |               |
|                  |            |                      |                 |                    | GBS: 0.3 E. coli: 0.2           | NA            |
|                  | BPSU[20]   | 2014–2015 All LBs    | 914,132         | ≤6                 | GBS: 0.57                       | 27/517, 5.2%  |
|                  |            | VLBWs                | 7569            | ≤6                 | E. coli: 2.24                   |               |
| The Netherlands  | AMC-RVIM[19]| 1987–1999 All LBs   | NA              | <7                 | GBS: 0.11                       | NA            |
|                  |            | All LBs              | NA              | <7                 | GBS: 0.19                       |               |
| Asia             | Five NICUs[15]| 2005 All LBs        | 35,294          | ≤2                 | All pathogens: 0.72             | 6/47, 12.8%   |
|                  |            | in China, Kuwait,    |                 |                    | GBS: 0.51                       | 4/18, 22%     |
|                  |            | Malaysia, Thailand   |                 |                    | GNB: 0.15                       | 2/17, 12.5%   |
|                  | Three NICUs[16]| 2006–2009 All LBs | 76,141          | <3                 | All pathogens: 0.62             | 13/181, 7.2%  |
|                  |            | in China, Malaysia,  |                 |                    | GBS 0.24                        |               |
|                  |            | Thailand             |                 |                    | GNB: 0.11                       |               |
|                  | China[17]  | 2015–2018 All LBs < 34 weeks | 19,084 | <3 | All pathogens: 9.7 | 42/186, 22.6% |

EOS: Early-onset sepsis; LBs: Live births; NICHD: National Institute of Child Health and Human Development; BPSU: British Paediatric Surveillance Unit; AMC-RVIM: Netherlands Reference Laboratory for Bacterial Meningitis of the Amsterdam Medical Center and the National Institute of Public Health and the Environment; NICU: Neonatal intensive care unit; VLBW: Very low birth weight; NA: Not available; GBS: Group B *Streptococcus*; GNB: Gram-negative bacilli.
In VLBW infants than in those with a BW >1500 g. In the Netherlands, despite IAP guidelines to prevent GBS EOS on the basis of culture-based screening at 35 to 37 week’s gestation, the incidence of GBS EOS increased slightly over the last two decades, demonstrating a similar secular trend as in the UK [Table 1].[14] In the UK, five serotypes (Ia, Ib, II, III, V) accounted for 377 (94%) of all isolates GBS strains, with the predominant serotypes being III (60%) and Ia (17%).[20] A particular concern is the large number of isolates identified as sequence type ST17, a clone associated with a high risk of invasive neonatal sepsis and meningitis.[21] Thus, much hope lies on a vaccine against GBS which is still under development.[22]

**China**

Currently, no standard guidelines exist for maternal GBS screening and neonatal GBS disease prevention in China. While some hospitals perform IAP following a risk-based strategy, others apply universal screening recommended by ACOG. A recent systematic review of published data from Chinese literature revealed that the maternal GBS colonization rate in the mainland of China may range from 5.7% to 14.5% among institutions.[23] Based on so far the largest population-based surveillance study for GBS disease burden from 18 urban tertiary hospitals across 16 Chinese provinces (2015–2017), the overall incidence of invasive GBS disease in infants ≤3 months of life was estimated to be 0.31 (95% CI 0.27–0.36) cases per 1000 LBs, ranging from 0 to 76 cases per 1000 LBs across participating hospitals.[24] The incidence of early- and late-onset GBS disease was 0.18 (95% CI 0.15–0.22) and 0.13 (95% 0.11–0.16) per 1000 LBs, respectively.[24] The majority (76.6%) of invasive GBS disease occurred in term infants, and only 13.2% of GBS-case mothers received GBS screening during pregnancy.[24] Similar to the UK, five serotypes (Ia, Ib, II, III, and V) accounted for the majority of GBS invasive cases in the mainland of China, and isolated GBS strains were most commonly III serotype and ST 17.[23,24] Due to population characteristics and sociocultural background, the actual rate of maternal GBS colonization and neonatal GBS diseases in China may differ greatly from those reported in industrialized countries, and are probably much lower based on current knowledge. Unresolved issues remain as to whether GBS screening and prevention protocols should be incorporated in China, and if so, what kind of strategies. As such, immunizing pregnant women against GBS, despite being an emerging approach to protect neonates from GBS disease in some countries, could not yet be introduced in China.

So far, chorioamnionitis as a significant risk factor of neonatal EOS has not been fully appreciated in China. It has been suggested that pathological and microbiological examination of the placenta should be routinely performed, especially in preterm deliveries, in order to better assess EOS and combined perinatal co-morbidities.[24] Notably, the predominance of nosocomial and opportunistic pathogens (eg, GNB and CoNS) among neonatal EOS cases in China raised the concern of possible unhygienic practices or inappropriate perinatal exposure to antibiotics favoring intestinal translocation of GNB.[17]

**Europe**

In contrast to universal maternal screening, risk-based stratification has been adopted in other industrialized countries.[12,13,19] Based on a prospective national surveillance of invasive GBS in infants younger than 90 days from 2014 to 2015 in the UK and Ireland, the incidence of all GBS infection was 0.94 (95% CI 0.88–1.00) per 1000 LBs, with GBS EOS being 0.57 (95% CI 0.52–0.62) per 1000 LBs.[20] The case fatality rate of GBS EOS was 5.2%, lower than that in the US [Table 1][10,11,20] Notably, both the incidence and case fatality rate were about five-fold higher
Late-Onset Neonatal Sepsis

Maternal post-partum transmission of GBS is underestimated

LOS still accounts for about one-third of neonatal GBS sepsis, and the case fatality rate of GBS LOS was higher than that of GBS EOS (7.7% vs. 5.2%).[20] Mother-to-infant transmission may constitute an important source of GBS LOS. A longitudinal study was carried out in 160 mother-baby pairs from Italy to assess postnatal colonization with GBS and the impact of IAP.[26] Specimens from the rectum, vagina, and milk of mothers were collected from the time of delivery to 8 weeks post-partum. Women were grouped into culture-positive carriers (n=83), culture-negative carriers (n=26), and non-carriers (n=51) at discharge from hospital. A total of 35 (22%) neonates were colonized by GBS from at least one body site, and the majority of them (30/35) were born to culture-positive carriers. Infants of culture-positive carriers exposed to IAP were less likely to be colonized (15/57 vs. 15/26, P=0.01), or heavily colonized (7/57 vs. 1/26, P=0.04). However, neonates exposed to IAP and discharged GBS-free from hospital often became subsequently colonized (12/57 vs. 1/26, P=0.09), and six out of 83 culture-positive carrier mothers showed positive milk cultures with heavy colonization of GBS in their babies. Molecular typing analysis confirmed identical GBS strains in all mother-baby pairs. These data call the attention of physicians to maternal transmission after delivery as an underestimated source of neonatal LOS.

GNB are associated with severe neonatal LOS

Despite being less common than Gram-positive bacteria to cause neonatal LOS, GNB are associated with more severe clinical manifestations such as meningitis, and have a higher mortality, especially in VLBW infants.[27] E. coli is the most common cause of bacterial meningitis in preterm infants and the second most common after GBS in term neonates in the UK.[28] In France, the average number of LBs each year was around 800,000 between 2001 and 2013, of whom 66.6% were born preterm.[29] In 2001, the Pediatric Infectious Group of the French Pediatric Society (GPIP/ACTIV) established an active bacterial pediatric meningitis surveillance network including 233 pediatric wards and 168 microbiology laboratories. From 2001 to 2013, 325 infants were prospectively diagnosed with E. coli meningitis, which was seven-fold more frequent in preterm than in term infants.[30] The median age at diagnosis was 14 days, with 2 peaks of infection onset at 0 to 3 days of age (EOS in mostly preterm neonates), and 11 to 15 days of age (LOS in mostly term infants). Severe clinical manifestation was reported in 51.9% of patients, and 9.2% died. Death was associated with very preterm birth (odds ratio [OR]: 7.3, 95% CI 2.7–20.9; P<0.001), cerebrospinal fluid (CSF) to blood glucose ratio <0.1 (OR: 15.3, 95% CI 1.8–128.3; P=0.012), uncom strains like O7 serogroup (P=0.034), and PapGII adhesin (OR: 2.3, 95% CI 1.2–4.5; P=0.015). Translocation of GNB into the systemic circulation via an interrupted gastrointestinal barrier has been speculated to be a key mechanism of GNB LOS.[27,31] Pathogen profiles of community- and hospital-acquired neonatal LOS

An emerging body of evidence has demonstrated completely different microbiological findings between various types of sepsis. This is of critical importance to guide empirical antibiotic therapy strategy, which should not only be adapted to the timing (early vs. late), but also to circumstances (hospital- vs. community-acquired).

Industrialized countries

To assess the epidemiology and types of neonatal sepsis, all newborn infants with blood culture-proven sepsis admitted to neonatal intensive care units (NICUs) in Switzerland between 2011 and 2015 were included.[7] Infants with LOS were classified as community- or hospital-acquired LOS if onset of infection was ≤48 or >48 h following admission. In 429 infants there were 444 episodes of blood culture-proven sepsis, with 20%, 62%, and 18% being EOS, hospital-acquired LOS, and community-acquired LOS, respectively. Correspondingly, the estimated incidence was 0.28, 0.86, and 0.28 per 1000 LBs, and case fatality 18%, 12%, and 0%, respectively. Major pathogens were GBS, other Gram-positive bacteria, and E. coli for EOS; GBS and E. coli for community-acquired LOS. In contrast, CoNS, Staphylococcus aureus, and other GNB were mostly isolated in hospital-acquired LOS.[7]

Non-industrialized countries

The burden of neonatal infections in developing countries is highly variable, maybe because of the lack of vital registries and surveillance systems.[32] Information about community-acquired bacteremia in South Asia and Southeast Asia was approached through a review of 17 eligible studies enrolling 40,644 patients.[33] Pathogenic organisms were isolated in 1722 (7%) of 26,258 children. Salmonella enterica serotype Typhi was the most common bacterial pathogen. Other commonly isolated organisms in children were Streptococcus pneumoniae and Haemophilus influenzae, probably reflecting the lack of large-sale vaccination. Severe bacterial infections are a leading cause of death among neonates in low-income countries with poor hygiene and frequent exposure to antibiotics without documentation of bacterial infection, resulting in the emergence and spread of multi-resistant bacteria.[34] With advancing pediatric healthcare, the use of central venous catheters (CVC) has become a fundamental part of neonatal and pediatric intensive care.[35] Maximal sterile barrier precautions have been shown to independently contribute to decreased CVC-associated bloodstream infection in VLBW infants.[36] Currently, there is a lack of population-based data on the pathogen profile of neonatal LOS in China. Gram-positive bacteria, mainly CoNS and S. aureus, were indicated as being responsible for the majority of neonatal LOS, while E. coli and Klebsiella spp. may account for most GNB LOS.[16,37-41] Most hospital-acquired LOS occurred in very preterm infants who were very likely to receive some kind of ventilatory support and parenteral nutrition through a CVC.[42]
Neonatal Viral Sepsis

The incidence of overall viral sepsis

Viruses are common but largely underappreciated pathogens of neonatal sepsis. In a population-based pregnancy surveillance at five sites in Bangladesh, India, and Pakistan from 2011 to 2014, babies with illnesses meeting the World Health Organization definition of possible serious bacterial infections (pSBI) were referred to study physicians for culture and molecular assays of blood and respiratory samples.[10] Among 63,114 babies, 6022 pSBI bacterial infections (pSBI) were referred to study physicians for culture and molecular assays of blood and respiratory samples.[10] Among 63,114 babies, 6022 pSBI bacterial episodes were identified (95.4 per 1000 LBs), with causes specified in 28% of episodes (16% bacterial and 12% viral). The mean incidence of bacterial and viral infections was 13.2 (95% credible interval 11.2–15.6) and 10.1 (95% credible interval 9.4–11.6) per 1000 LBs, respectively. The leading viral pathogen was respiratory syncytial virus (5.4 per 1000 LBs). This study was among the first to provide valuable population-based data on neonatal viral sepsis with universal detection of pathogen species. So far, species-specific data on neonatal viral sepsis are limited.

Herpes simplex virus (HSV)

HSV may cause potentially devastating infection in neonates. However, large-scale assessment of its frequency in potentially infected infants has not been performed, apart from one retrospective cross-sectional study in 23 North American pediatric emergency departments enrolling infants ≤60 days old with CSF samples for HSV polymerase chain reaction (PCR) or culture.[43] Of 26,533 eligible encounters, 112 infants had HSV identified (0.4%), corresponding to 1.2% of all infants tested for HSV. Among them, 90 (80.4%) occurred in weeks 1 to 4, with the median age of HSV-infected infants being 14 days (interquartile range 9–24 days). Notably, 68 of 112 test-positive infants had central nervous system (CNS) or disseminated HSV disease. The proportion of infants subjected to an HSV test (35%, range 14%–72%) and to whom acyclovir was administered (23%, range 4%–53%) varied widely across centers. Thus, both pediatric emergency physicians and neonatologists should keep in mind this rare but deadly cause of neonatal sepsis, which requires urgent acyclovir administration. A careful review of the maternal history and close communication with obstetricians are critical for a timely diagnosis and treatment of neonatal HSV disease.

Enteroviruses

Enteroviruses have been increasingly recognized to be causes of meningitis, sepsis-like disease, and fever without source in neonates and older children. A prospective multicenter study performed at 35 French pediatric and emergency departments has shown that positive blood PCR results for enterovirus was common.[44] Between 2015 and 2016, a total of 71 newborns were subjected to enterovirus testing, the detection of enterovirus was more frequent in blood than in CSF (70/71 vs. 62/71, P = 0.011). As such, PCR for enterovirus should be part of the sepsis workup in neonatal sepsis, and empiric antibiotic therapy should be promptly discontinued in confirmed cases of viral infection. So far, there is a lack of population-based data on neonatal infection due to enterovirus in China. In a hospital-based prospective study in a level-3 NICU in East China, enterovirus infection among febrile neonates with an admission temperature >38°C was diagnosed by PCR testing of stool and/or CSF samples.[45] One-hundred thirty (39.2%) of 334 febrile neonates had PCR-confirmed enterovirus infection, with PCR results being positive in 130 (99.2%) of stool and in 58 (44.3%) of CSF samples, respectively. Among 131 infected neonates, mostly term infants in their 2 to 3 postnatal weeks, 69 (52.7%) had diarrhea, 48 (36.6%) respiratory symptoms, 22 (16.8%) poor feeding, 34 (26.0%) rash, and 18 (13.7%) lower platelet counts <150 × 10^9/L.[45] These data indicate that enterovirus infection may be common in febrile neonates and stool samples should be included in diagnostic work-up. Although all infected patients received supportive treatment with none developing fulminant disease course, the long-term outcome of neonates infected with enterovirus may be worrying. Another case series of 12 Chinese neonates with a GA of 35 to 39 weeks showed that enterovirus can cause severe encephalitis associated with white matter damage in the neonatal period, and the severity of the imaging abnormalities might correlate with later neurodevelopmental outcome.[46]

Infectious Work-up of Neonatal Sepsis

Initial signs and symptoms of neonatal sepsis are often mild and not specific. Infected infants are likely to appear generally ill, without fever or system-related symptoms. However, the disease course may also be fulminant with development of septic shock, respiratory distress, neurological dysfunction, and even death. As such, a prompt and adequate infectious work-up is essential for timely diagnosis of neonatal sepsis and the prevention of adverse outcomes.

Culture-dependent and independent tests

Sufficient amount (1–2 mL) of blood should be taken to optimize the yield of blood culture,[47] besides the volume needed for a full blood cell count, venous pH, and lactate, and other parameters to assess the disease status [Table 2]. Urine sample obtained via aseptic bladder catheterization and CSF via lumbar puncture (LP) should be considered in a respiratory- and hemodynamically-stable infant.[48–50] A positive bacterial culture after 24 to 36 h confirm the type of bacterial pathogen, and allows antimicrobial susceptibility testing.[42] Biological markers, such as procalcitonin (PCT), C-reactive protein (CRP), white blood cell, and absolute neutrophil count (ANC), are not specific of bacterial infection. However, the Lab-score based on PCT levels (<0.5, ≥0.5, and ≥2 ng/mL), CRP levels (<40, 40–99, and ≥100 mg/L), and urine dipstick (negative or positive) has been shown to be highly predictive of a urinary tract infection (UTI).[51] Nonetheless, UTI should be defined by bacterial counts of uropathogen (mostly E. coli), with the minimum concentration ranging between 10^9 and 10^10 colony-forming units/mL.[52] Recently, two prediction rules to identify young febrile infants at risk of SBI in the pediatric emergency department have been validated. The “Step-by-Step” approach developed in
Europe assesses abnormal clinical appearance at first, followed by young age (<3 weeks), significant leukocytosis and bacteremia confirmed by high-power field microscope, PCT > 0.5 ng/mL, CRP > 20 mg/L, or ANC > 10,000/mm³ to define low-risk and high-risk of SBI. The prediction rule of the PECARN group in USA identifies febrile infants 60 days or younger at low risk of SBI using the urinalysis, ANC, and PCT levels.\[^{54}\]

**Empirical Treatment of Neonatal Sepsis**

**Timing and regimen of antibiotics**

Empirical antibiotic treatment should be initiated as soon as neonatal sepsis is suspected, in fear of negative outcomes associated with missed septic cases. As streptococci are often sensitive to penicillin/ampicillin and about 50% of *E. coli*, noticeably K1, are resistant to ampicillin/amoxicillin, most recommendations of treating neonatal EOS are now to combine amoxicillin/ampicillin with gentamicin.\[^{5,60}\] If culture confirms GBS, amoxicillin/ampicillin is recommended, and gentamicin should be discontinued after 48 h to prevent cumulative nephro- and oto-toxicity.\[^{61,62}\] In case of ampicillin-resistant *E. coli* infection, a third-generation cephalosporin like cefotaxime should be used (100 mg/kg per day), and at a higher dosage (200 mg/kg per day) when meningitis is suspected. In case of hospital-acquired LOS which is often caused by CoNS like *Staphylococcus epidermidis*, vancomycin by intravenous injection (or continuous infusion through a CVC if it is infected) is recommended at first.\[^{63,64}\] As many of CoNS are indeed methicillin-resistant. When culture results are positive for GNB, aminoglycoside is preferred given its narrow spectrum and reduced risk of resistance.\[^{5}\] However, escalation to third-generation cephalospoprin and even carbapenem should be considered, depending on local epidemiology, clinical presentation especially with CNS involvement, and whether there is evidence of ESBL Enterobacteriaceae.\[^{5}\] As community-acquired LOS is

---

**Table 2: Neonatal sepsis workup.**

| Parameter             | Test   | Optimal conditions for specimen collection | Value in diagnosing neonatal sepsis |
|-----------------------|--------|-------------------------------------------|-----------------------------------|
| **Infectious markers**|        |                                            |                                   |
| Blood                 | Culture| 1–2 mL of blood                           | Standard for bacteremia           |
| Urine                 | Culture| Bladder catheterization                   | Gold standard for UTI             |
| CSF                   | Culture| Non-traumatic lumbar puncture             | Standard for meningitis           |
| Nasopharyngeal        | PCR    | Winter epidemics, contact with a sick case; Nasal aspirates for RSV, nasal swab for influenza virus | Discuss plausibility and PCR positivity: possible respiratory tract infection |
| **Biological markers**|        |                                            |                                   |
| pH, ABG, lactate      | Blood  | Arterial or venous sampling                | Lactate > 2 mol/L (indicate shock) |
| ANC                   | Blood count | Take into account the potential normal range for postnatal age | Neutropenia < 1,500,000/mm³ (not specific of bacterial infection) |
| Platelets             | Blood count | No clotting sampling                      | Thrombocytopenia < 50,000/mm³ (not specific) |
| PCT                   | Blood  | 2–6 h after onset of infection             | > 2 ng/mL (not specific)          |
| CRP                   | Blood  | 8–24 h after onset of infection            | > 20 mg/L (not specific)          |
| Sepsis scores         | Multiple test | 24 h after onset of sepsis                 | Useful for low-risk SBI          |

CSF: Cerebrospinal fluid; ABG: Arterial blood gases; ANC: Absolute neutrophil count; PCT: Procalcitonin; CRP: C-reactive protein; PCR: Polymerase chain reaction; RSV: Respiratory syncytial virus; UTI: Urinary tract infection; SBI: serious bacterial infection; IF: Immunofluorescence.

---

**Particularities of LP**

LP is mandated in young febrile infants if sepsis is highly suspected and the patient’s condition allows.\[^{53-55}\] The previously recommended practice of performing brain imaging before a LP has been shown to significantly delay antibiotic treatment and increase the likelihood of a poor neurologic outcome, both in adults and children with proven bacterial meningitis.\[^{56,57}\] As a traumatic LP can complicate the interpretation of CSF, it is helpful to evaluate the mean spinal canal depth (MSCD) using either the following rule MSCD (mm) = 0.4 × weight (kg) + 20 or direct ultrasound imaging.\[^{58}\] Direct examination of CSF sample under microscope is mandatory to determine the bacterial type and number per high-power field, providing valuable guidance for empirical antibiotic therapy. The presence of Gram-positive cocci in long chains under microscope may suggest GBS meningitis, and Gram-negative bacilli meningitis caused by *E. coli* or even extended-spectrum beta-lactamase (ESBL) *Enterobacteriaceae*, depending on microbial surveillance results at the local institutions. In a multicenter study in Asia which included 453 documented episodes of neonatal sepsis, the most common pathogens for neonatal meningitis were *Klebsiella* spp. (27/76), followed by CoNS (11/76) and *E. coli* (10/76), with GBS identified only in one case.\[^{15}\] One recent province-level multicenter study in South China including 838 cases of neonatal meningitis from 12 hospitals (2011–2016) showed that the first three causes were GBS (88/249), *E. coli* (55/249), and CoNS (32/249).\[^{59}\]
often related to respiratory viral infections, antibiotic treatment must be rapidly discontinued when viral infections is confirmed by multiplex PCR of nasopharyngeal aspirates.

The duration of antibiotic treatment

Recently, two statements regarding the management of neonates born at <35 and >35 weeks' gestation with suspected or proven early-onset bacterial sepsis have been released in the US. [66,67] Suspected EOS should always be confirmed by cultures of blood, urine or CSF, and antibiotic therapy should be discontinued if cultures are sterile. [66,67] This rule also applies to the management of LOS. Furthermore, non-specific biological markers (e.g., blood cell count, PCT, CRP) alone do not justify prolonged use of antibiotics. [66,67] A fruitful dialogue should be maintained between neonatologists and microbiologists to optimize the duration of antibiotic treatment, which relies often upon empirical rules: 7 to 10 days for bacteremia, 14 days for Gram-positive meningitis, and 21 days for Gram-negative meningitis. [3,68] Given the general trend to shorten antibiotic therapy and minimize the selection of multi-resistant bacteria, PCT as a highly sensitive biomarker of sepsis has been investigated to guide the cessation of antibiotic therapy. [70]

Overuse and misuse of antibiotics contribute to microbial resistance

Both the inappropriate overuse of broad-spectrum antibiotics, such as third-generation cephalosporins and carbapenem, and inadequacy of antibiotic stewardship have led to the emergence of multi-resistant bacteria, mostly ESBL Enterobacteriaceae, in neonatal sepsis in China. [71] In a retrospective study reporting the temporal trend of antimicrobial resistance over a period of 25 years in the largest neonatal unit in Southwest China, a dramatic six- and two-fold increase was found in the resistance rate of ceftazidime and imipenem respectively, in Klebsiella spp. isolated from neonates with sepsis. [38] A recent meta-analysis of Chinese literature (2009–2014) on neonatal sepsis revealed that more than 50% of E. coli and Klebsiella spp. were resistant to third-generation cephalosporin, and ampicillin resistance of E. coli was almost 80%, [37] similar to that in the US (85%). [11] Unsurprisingly, the resistance rate of amikacin was relatively low (around 10%–15%) in E. coli and Klebsiella spp., [37] probably due to the fact that aminoglycoside is not routinely used to treat neonatal sepsis in China. Carbapenem-resistance was found in 9% of E. coli and 6% of Klebsiella spp., respectively. [37] Similar antibiotic susceptibility results of GNB were corroborated by other systematic reviews and web-based surveys. [12,13] As for Gram-positive bacteria, although resistance to glycopeptide including vancomycin and linezolid seem to be rare in China, methicillin resistance was reported for 60% to 70% of Staphylococcus spp. [17,18,40]

Antimicrobial resistance in developing countries, such as India [74] and Egypt [75] is alarming. A very recent report from a multinational, multicenter online database showed that third-generation cephalosporin resistance rates among Gram-negative isolates ranged from 26% to 84%, and carbapenem resistance rates ranged from 0% to 81% in 12 low- and middle-income countries. [73] Glycopeptide resistance rates among Gram-positive bacteria ranged from 0% to 45%. [73] Staff to patient ratio and antibiotic availability were considered to be key factors affecting antimicrobial resistance rate in these settings. [34] The rising antibiotic resistance very much complicates both the choice of initial empirical antibiotic treatment and secondary antibiotic strategy, as last-resource antibiotics are not readily accessible in many settings. [76]

To minimize the selection of multi-resistant bacteria, there is an urgent need to restrict antibiotic therapy to proven neonatal bacterial infection and shorten antibiotic course. Furthermore, surveillance and assessment of antibiotic consumption has been demonstrated to positively influence antibiotic stewardship strategy and reduce antibiotic use. [77] Screening for GNB on neonatal body sites may have a predictive value in neonatal LOS, [78] and decolonization has been investigated as an approach to prevent sepsis and the spread of multi-resistant GNB. [79] However, the prognostic value of routine screening of neonatal microbial colonization remains controversial, due to a lack of high-quality evidence, especially in VLBW infants. [31,78]

Supportive treatment of neonatal sepsis: uncertainties and certainties?

Neonatal sepsis can progress to septic shock, which may requires volume loading and vasopressors in order to maintain organ function. However, after the publication of the paradoxical results of the fluid expansion as supportive treatment (FEAST) trial comparing repeated boluses of 20 mL/kg of either saline or 5% albumin with no bolus in 3141 African children with severe infection, [80] there is now a trend to restrict unnecessary volume loading in order to stabilize hemodynamics while preventing the occurrence of brain and lung edema, especially in resource-limited settings. [81]

For years, intravenous immunoglobulins (IVIG) have been used in severe neonatal sepsis, because newborns are relatively deficient in endogenous immunoglobulins. However, a large phase III clinical trial of 3493 infants at 113 hospitals comparing two iv infusions of 500 mg (10mL) per kg body weight 48 h apart with placebo failed to demonstrate a significant difference in the incidence of subsequent sepsis episodes and the rates of major or non-major disability at 2 years of follow-up. [82] Since the large clinical trial included neonates from both developing and developed countries, the negative results should be interpreted as high-level evidence to abandon IVIG administration among septic neonates in China.

Conclusions

To sum up, the epidemiology and pathogen profile of neonatal sepsis may differ substantially between countries and regions, and data from elsewhere should always be interpreted with caution before being extrapolated to any local institution in China. The alarmingly high
antimicrobial resistance rate of pathogens causing neonatal sepsis in China poses a substantial challenge, given its very large annual birth population. Emphasis is laid on continuous monitoring of a priori antibiotic susceptibility of the causative micro-organisms. Notably, viral infection may mimic clinical signs of bacterial sepsis but require antiviral therapy (or no therapy) instead of antibiotics. There is an urgent need for the early diagnosis of neonatal sepsis followed by adequate and appropriate empirical therapy. Equally important is the early cessation of antimicrobial antibiotic treatment as soon as negative microbial evidence has been yielded, despite the presence of isolated abnormal inflammatory markers. Last but not the least, efficient communication with both obstetricians for reliable maternal history and microbiologists for culture results is strongly recommended, especially in resource-limited settings in China, to optimize the regimen and duration of antibiotic treatment.

Acknowledgements

The authors would like to warmly thank Dr. Robert Ross-Russell, Director of Studies in Medicine, Peterhouse, Cambridge, UK, and Chair of the European Board of Pediatrics for his kind editorial assistance. We also thank Wolters Kluwer Health, Inc. and Elsevier for authorizing the citation of Supplementary Figures 1, http://links.lww.com/CM9/A244, http://links.lww.com/CM9/A245, http://links.lww.com/CM9/A246 and 2, http://links.lww.com/CM9/A247, http://links.lww.com/CM9/A248 in our manuscript.

Conflicts of interest

None.

References

1. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the sustainable development goals. Lancet 2016;388:3027–3035. doi: 10.1016/S0140-6736(16)31593-8.

2. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Renhart K, Kissou N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med 2018;6:223–230. doi: 10.1016/S2214-109X(18)30063-8.

3. Wang H, Yue H, Sun B, Zhu X, Niu H, Qi T, et al. Birth population survey in Huai’an in 2015: perinatal-neonatal mortality and preterm birth rate in emerging regions in China. J Matern Fetal Neonatal Med 2020;33:838–846. doi: 10.1080/14767058.2018.1506439.

4. He C, Chu Y, Perin J, Dai L, Li X, Miao L, et al. National and subnational all-cause and cause-specific child mortality in China, 1996-2015: a systematic analysis with implications for the sustainable development goals. Lancet Global Health 2017;5:e186–e197. doi: 10.1016/S2214-109X(16)30334-5.

5. Shane A., Sánchez Pj, Stoll Rj. Neonatal sepsis. Lancet 2017;390:1770–1780. doi: 10.1016/S0140-6736(17)31002-4.

6. Goldenberg RL, Hauth JC, Andrews WW. Intraterine infection and preterm delivery. N Engl J Med 2000;342:1500–1507. doi: 10.1016/S0140-6736(13)31002-4.

7. Giannoni E, Agyeman PKA, Stocker M, Posfay-Barbe KM, Heiningier U, Sprecher BD, et al. Neonatal sepsis of early onset, and hospital-acquired and community-acquired late onset: a prospective population-based cohort study. J Pediatr 2018;200:106–114. doi: 10.1016/j.pediatr.2018.05.048.

8. Saha S, Schrag SJ, Arifeen SE, Mullany LC, Shahidul Islam M, Shang N, et al. Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA); an observational cohort study. Lancet 2018;392:145–159. doi: 10.1016/S0140-6736(18)30871-2.

9. Schrag SJ, Farley MM, Petit S, Reingold A, Weston EJ, Pondo T, et al. Epidemiology of invasive early-onset neonatal sepsis, 2003 to 2014. Pediatrics 2016;138:e2016052021. doi: 10.1542/peds.2016-052021.

10. Stoll BJ, Hansen NL, Sanchez PJ, Faix RG, Pinto DX, Van Meurs KP, et al. Early onset neonatal sepsis: the burden of Group B Streptococcal and E. coli disease continues. Pediatrics 2011;127:812–826. doi: 10.1542/peds.2010-2217.

11. Tiskumara R, Fakharee SH, Liu CQ, Nuntnarumit P, Lui KM, Hammond M, et al. Neonatal infections in Asia. Arch Dis Child Fetal Neonatal Ed 2009;94:F144–F148. doi: 10.1136/adc.2008.159865.

12. Al-Taiar A, Hammond MS, Cuiqing L, Lee JK, Lui KM, Nakwanz L, et al. Neonatal infections in China, Malaysia, Hong Kong and Thailand. Arch Dis Child Fetal Neonatal Ed 2013;98:F249–F255. doi: 10.1136/archdischild-2012-301767.

13. Jiang S, Hong L, Gai J, Shi J, Yang Y, Lee SK, et al. Early-onset sepsis among preterm neonates in China, 2013 to 2015. Pediatr Infect Dis J 2019;38:1236–1241. doi: 10.1097/INF.0000000000002492.

14. Prevention of group B Streptococcal early-onset disease in newborns: ACOG committee opinion, number 797. Obstet Gynecol 2020;135: c71–c72. doi: 10.1097/AOG.0000000000006369.

15. Britter R, Biggs MW, van de Beek D, Kuipers TW, van der Ende A. Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis 2014;14:1083–1089. doi: 10.1016/S1473-3099(14)70919-3.

16. O’Sullivan CP, Lamagni T, Patel D, Efstatiou A, Cumny M, Meehan M, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014-15: a prospective surveillance study. Lancet Infect Dis 2019;19:83–90. doi: 10.1016/S1473-3099(18)30553-3.

17. Kao Y, Tsai M-H, Lai M-Y, Chu S-M, Huang H-R, Chang M-C, et al. Emerging serotype III sequence type 17 group B streptococcus invasive infection in infants: the clinical characteristics and impacts on outcomes. BMC Infect Dis 2019;19:538. doi: 10.1186/s12879-019-4477-y.

18. Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambdo D, et al. Group B streptococcal vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis 2016;16:546–555. doi: 10.1016/S1473-3099(15)00484-3.

19. Huang J, Lin XZ, Zhu Y, Chen C. Epidemiology of Group B streptococcal infection in pregnant women and diseased infants in China. Pediatr Neonatol 2019;60:387–395. doi: 10.1016/j.ped.2019.07.001.

20. Ji W, Liu H, Madhi SA, Cunningham M, Zhang Z, Danger Z, et al. Clinical and molecular epidemiology of invasive Group B streptococcal disease among infants. China Emerg Infect Dis 2019;25:2021–2030. doi: 10.3201/eid2511.18118477.

21. Han X, Du H, Cao Y, Zhang Y, Zhang J, Zhang L, et al. Association of histological and clinical chorioamnionitis with perinatal and neonatal outcome. J Matern Fetal Neonatal Med 2019;1–9. doi: 10.1080/14767058.2018.1618824.

22. Berardi A, Rossi C, Centi R, Chiari M, Gherardini G, Venturrelli C, et al. Group B streptococcal colonization in 160 mother-baby pairs: a prospective cohort study. J Pediatr 2013;163:1099–1104. doi: 10.1016/j.jpeds.2013.05.064.
32. Thaver D, Zaidi AKM. Burden of neonatal infections in developing countries of South and Southeast Asia: a systematic review. Lancet Infect Dis 2012;12:480–487. doi: 10.1016/S1473-3099(12)70028-2.

41. Lin HJ, Du LZ, Ma XL, Shi LP, Pan JH, Tong XM. Mortality and morbidity of extremely low birth weight infants in the mainland of South China (in Chinese). Chin J Pediatr 2018;56:421–426. doi: 10.1016/j.ijcpid.2018.05.006.

51. Galetto-Lacour A, Zamora SA, Andreola B, Bressan S, Lacroix L, Da Xue J, et al. Assessment of blood enterovirus testing in pediatric populations of parts of South China (in Chinese). Chin J Pediatr 2018;56:706–712. doi: 10.1016/j.ijcpid.2018.05.006.

58. Liu JY, Chen SQ, Yan YY, Hu YY, Wei J, Wu QP, et al. Identification and antimicrobial resistance of pathogens in neonatal septicaemia in China: a meta-analysis. Int J Infect Dis 2018;71:89–93. doi: 10.1016/j.ijid.2018.04.794.

67. Lu Q, Zhou M, Tu Y, Yao Y, Yu J, Cheng S. Pathogen and antimicrobial resistance profiles of culture-proven neonatal sepsis in Southwest China. J Paediatr Child Health 2016;52:939–943. doi: 10.1111/jpc.13278.

27. Dong Y, Glaser K, Speer CP. Late-onset sepsis caused by Gram-negative bacteria in very low birth weight infants: a systematic review. Expert Rev Antimicrob Ther 2015;12:177–188. doi: 10.1080/14787935.2015.10568871.

46. Wu T, Fan XP, Wang WY, Yuan TM. Enterovirus infections are associated with white matter damage in neonates. J Paediatr Child Health 2014;50:817–822. doi: 10.1111/jpc.12666.

54. Kuppermann N, Dayan PS, Levine DA, Vitale M, Tzimenatos L, Tourtellotte J, et al. A clinical prediction rule to identify febrile infants 60 days and younger at low risk for serious bacterial infection. JAMA Pediatr 2015;173:342–348. doi: 10.1001/jamapediatrics.2018.5501.

80. Nguyen T, Jeyakumar A, Nuoel L. Lumbar puncture performed promptly or after neuroimaging in acute meningitis in adults: a prospective national cohort study evaluating different guidelines. Clin Infect Dis 2018;66:321–328. doi: 10.1093/cid/ciy080.

88. Nguyen T, Jeyakumar A, Nuoel L. Lumbar puncture performed promptly or after neuroimaging in acute meningitis in adults: a prospective national cohort study evaluating different guidelines. Clin Infect Dis 2018;66:321–328. doi: 10.1093/cid/ciy080.

28. Okike IO, Johnson AP, Henderson KL, Blackburn RM, Muller-Pebby B, Laditana SN, et al. Incidence, aetiology, and outcome of bacterial meningitis in infants aged < 90 days in the UK and Republic of Ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis 2014;59:e150–e157. doi: 10.1093/cid/ciu514.

29. Basmaci R, Bonacorsi S, Bidet P, Biran V, Aujard Y, Bingen E, et al. Nosocomial bacterial meningitis in neonates from 32 children from 2001 to 2013 in France. Clin Infect Dis 2015;51:779–786. doi: 10.1093/cid/civ367.

30. Basmaci R, Bonacorsi S, Bidet P, Biran V, Aujard Y, Bingen E, et al. Escherichia coli meningitis features in 325 children from 2001 to 2013 in France. Clin Infect Dis 2015;51:779–786. doi: 10.1093/cid/civ367.

31. Folgori L, Tersigni C, Hsia Y, Kortsalioudaki C, Heath P, Sharland M, et al. The relationship between Gram-negative colonization and bacteremia in neonates with suspected meningitis. Pediatr Infect Dis J 2009;28 (Suppl 1):S3–S9. doi: 10.1097/INF.0b013e3181958755.

32. Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y, et al. Neonatal bacterial meningitis: 444 cases in 7 years. Pediatr Infect Dis J 2011;30:212–217. doi: 10.1097/INF.0b013e3181fab1e7c.

33. Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y, et al. Neonatal bacterial meningitis: 444 cases in 7 years. Pediatr Infect Dis J 2011;30:212–217. doi: 10.1097/INF.0b013e3181fab1e7c.

34. Chessyre E, Goff Z, Bowen A, Carapetis J. The prevention, diagnosis, and antimicrobial resistance of pathogens in neonatal septicemia in developing countries in South and Southeast Asia: a systematic review. Lancet Infect Dis 2012;12:480–487. doi: 10.1016/S1473-3099(12)70028-2.

35. Chessyre E, Goff Z, Bowen A, Carapetis J. The prevention, diagnosis, and antimicrobial resistance of pathogens in neonatal septicemia in developing countries in South and Southeast Asia: a systematic review. Lancet Infect Dis 2012;12:480–487. doi: 10.1016/S1473-3099(12)70028-2.

36. Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y, et al. Neonatal bacterial meningitis: 444 cases in 7 years. Pediatr Infect Dis J 2011;30:212–217. doi: 10.1097/INF.0b013e3181fab1e7c.

37. Gaschignard J, Levy C, Romain O, Cohen R, Bingen E, Aujard Y, et al. Neonatal bacterial meningitis: 444 cases in 7 years. Pediatr Infect Dis J 2011;30:212–217. doi: 10.1097/INF.0b013e3181fab1e7c.

38. Chessyre E, Goff Z, Bowen A, Carapetis J. The prevention, diagnosis, and antimicrobial resistance of pathogens in neonatal septicemia in developing countries in South and Southeast Asia: a systematic review. Lancet Infect Dis 2012;12:480–487. doi: 10.1016/S1473-3099(12)70028-2.

39. Huyhn BT, Kermorvan-Duchemn E, Herindrany P, Padget M, Rakotomanna FMJ, Feno H, et al. Bacterial infections in neonates, Madagascar. Emerging Infect Dis 2018;24:710–717. doi: 10.3202/eid2404.161977.

40. Chessyre E, Goff Z, Bowen A, Carapetis J. The prevention, diagnosis, and antimicrobial resistance of pathogens in neonatal septicemia in developing countries in South and Southeast Asia: a systematic review. Lancet Infect Dis 2012;12:480–487. doi: 10.1016/S1473-3099(12)70028-2.

41. Lin HJ, Du LZ, Ma XL, Shi LP, Pan JH, Tong XM, et al. Mortality and morbidity of extremely low birth weight infants in the mainland of South China (in Chinese). Chin J Pediatr 2018;56:421–426. doi: 10.1016/j.ijcpid.2018.05.006.

42. Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. Arch Dis Child Fetal Neonatal Ed 2013;98:F257–F263. doi: 10.1136/adc.2013.306213.
of Pediatrics. Management of neonates born at \( \leq 34 \) 6/7 weeks' gestation with suspected or proven early-onset bacterial sepsis. Pediatrics 2018;142:e20182894. doi: 10.1542/peds.2018-2894.

67. Puopolo KM, Benitz WE, Zaoutis TE. Committee on fetus and neonate, Committee on infectious diseases of the American Academy of Pediatrics. Management of neonates born at \( 35 \) 0/7 weeks' gestation with suspected or proven early-onset bacterial sepsis. Pediatrics 2018;142:e20182896. doi: 10.1542/peds.2018-2896.

68. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267–1284. doi: 10.1086/425368.

69. Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: a systematic review of randomized clinical trials. Pharmacotherapy 2018;38:674–687. doi: 10.1002/phar.2118.

70. Stocker M, van Herk W, el Helou S, Dutta S, Fontana MS, Shuerman FABA, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet 2017;390:871–881. doi: 10.1016/S0140-6736(17)31444-7.

71. Zhang J, Folgori L, Hsia Y, Sharland M, Yang Y. Pattern of antibiotic resistance in bloodstream isolates from Chinese neonates. Pediatr Infect Dis J 2019;38:600–604. doi: 10.1097/INF.0000000000002246.

72. Ding Y, Wang Y, Hsia Y, Sharland M, Heath PT. Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Ann Clin Microbiol Antimicrob 2019;18:36. doi: 10.1186/s12941-019-0334-9.

73. Li G, Bielicki JA, Ahmed ASMNU, Islam MS, Berezin EN, Gallacci CB, et al. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child 2020;105:26–31. doi: 10.1136/archdischild-2019-316816.

74. Investigators of the Delhi Neonatal Infection Study (DeNIS) Collaboration. Characterisation and microbial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Global Health 2016;4:e752–e760. doi: 10.1016/S2214-109X(16)3048-6.

75. Nour I, Eldega HE, Nasef N, Shouman R, Abdel-Hady H, Shabaan AE. Risk factors and clinical outcomes for carbapenem-resistant Gram-negative late-onset sepsis in a neonatal intensive care unit. J Hosp Infect 2017;97:52–58. doi: 10.1016/j.jhin.2017.05.025.

76. Dona D, Sharland M, Heath PT, Folgori L. Strategic trials to define the best available treatment for neonatal and pediatric sepsis caused by carbapenem-resistant organisms. Pediatr Infect Dis J 2019;38:825–827. doi: 10.1097/INF.0000000000002381.

77. Cantey JB, Wozniak PS, Pruszensky JE, Sánchez PJ. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study. Lancet Infect Dis 2016;16:1178–1184. doi: 10.1016/S1473-3099(16)30205-5.

78. Seidel J, Haller S, Eckmanns T, Harder T. Routine screening for colonization by GNB in neonates at intensive care units for the prediction of sepsis: systematic review and meta-analysis. J Hosp Infect 2018;99:367–380. doi: 10.1016/j.jhin.2018.03.017.

79. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014;20 Suppl 1:1–53. doi: 10.1111/1469-0691.12427.

80. Mantland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011;364:2483–2493. doi: 10.1056/NEJMoa1101549.

81. Levin M, Cunnington AJ, Wilson C, Nadel S, Lang HJ, Ninis N, et al. Effects of saline or albumin bolus in resuscitation: evidence from re-analysis of the FEAST trial. Lancet Respir Med 2019;7:581–593. doi: 10.1016/S2213-2600(19)30114-6.

82. The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011;365:1201–1211. doi: 10.1056/NEJMoa1101549.

83. Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis 2018;18:e368–e378. doi: 10.1016/S1473-3099(18)30296-2.

How to cite this article: Dong Y, Basmaci R, Titomanlio L, Sun B, Mercier JC. Neonatal sepsis: within and beyond China. Chin Med J 2020;00:00–00. doi: 10.1097/CM9.0000000000000935.